Press Releases June 23, 2026 08:00 AM

Integra LifeSciences Announces Key Executive Appointments

Integra LifeSciences Strengthens Leadership Team with Key Executive Appointments to Drive Growth and Commercial Excellence

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences Corporation Holdings announced a series of leadership changes within its commercial organization, including new appointments and promotions aimed at enhancing customer focus, accelerating execution, and supporting the company’s long-term growth strategy. These changes involve executives leading key divisions such as Tissue Reconstruction, Specialty Surgery, and international business operations.

Integra LifeSciences Announces Key Executive Appointments
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Appointment of Robert T. Davis Jr. as EVP of Tissue Reconstruction and Distributed Technologies to lead wound reconstruction, soft tissue segments, and private label.
  • Promotion of Christopher Kilburn-Peterson to corporate VP and president for the Tissue Reconstruction division, responsible for strategic and commercial priorities.
  • Harvinder Singh named EVP and president of the Specialty Surgery division, with international business leadership aligning under the commercial organization.
  • These leadership changes aim to strengthen commercial execution and internal talent development within a global medical technology company impacting healthcare and medical devices sectors.

PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy.

Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Kilburn-Peterson has been promoted to corporate vice president and president for the Tissue Reconstruction division, reporting to Davis. He will be responsible for the division’s strategic direction, including commercial and portfolio priorities. Kilburn-Peterson most recently served as senior vice president and general manager of Acclarent, where he led the successful integration of the company’s ENT business.

Harvinder Singh, who previously led the international business, succeeds McBreen as executive vice president and president of the Specialty Surgery division, leading its commercial and portfolio strategy and business performance, and will report to him. With the international business aligned under McBreen’s commercial organization, the regional international leaders will now report directly to McBreen.

“These changes reflect our continued focus on commercial excellence, while developing internal talent and strengthening our leadership bench,” said Mike McBreen, executive vice president and chief commercial officer, Integra LifeSciences. “We are building strong management capabilities across the organization and positioning experienced leaders at the forefront of our market-facing activities. Bob, Chris, and Harvinder bring deep expertise, proven leadership, and a strong track record of execution that will help us deliver for customers and patients.”

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
[email protected]

Media Contact:
Laurene Isip
(609) 208-8121
[email protected]

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/daeb707f-cfa7-4617-beee-f00f28194901
https://www.globenewswire.com/NewsRoom/AttachmentNg/2a8e48ad-f79e-4610-ab74-287ac135fcbb
https://www.globenewswire.com/NewsRoom/AttachmentNg/1fb9e02a-375d-4a92-9208-657bee9ce339


Risks

  • Uncertain impact of leadership changes on execution and business outcomes during transition periods.
  • Potential challenges in integrating different divisions and geographic regions under new leadership structures.
  • Market and regulatory risks inherent in the medical technology sector could impact the effectiveness of growth strategies.

More from Press Releases

The U.S. Department of Energy Announces Conditional $17.5 billion Financing to Support Westinghouse Nuclear Reactor Deployment Jun 23, 2026 Old National Named to Points of Light ‘The Civic 50’ for 2026; Recognized as Financials Sector Leader Jun 23, 2026 TEGNA CEO Patrick Paolini Taps Seasoned Industry Leaders for Top Roles Jun 23, 2026 Safe Pro Awarded New $1.3 Million U.S. Government Subcontract to Integrate Real-Time AI Landmine Detection into Unmanned Ground Vehicles Jun 23, 2026 Eldorado Gold Named to Corporate Knights 2026 Best 50 Corporate Citizens in Canada Jun 23, 2026